Table 4.
Summary of concomitant drugs in in long-term administration group
| TP group | NTP group | ||
| n = 17 | n = 20 | P-value | |
| Number of concomitant drugs | 7.3±4.3 | 6.1±3.5 | 0.368b |
| Number of concomitant DTADEs | 4.6±2.3 | 3.0±1.7 | 0.023b |
| Concomitant drugs | |||
| Antimicrobial drugs, n (%) | 8 (47) | 6 (30) | 0.328c |
| Antibiotics, n (%) | 7(41) | 5 (25) | 0.482c |
| Trimethoprim-sulfamethoxazole, n (%) | 4 (24) | 0 (0) | 0.036c |
| Rifampicin, n (%) | 3 (18) | 0 (0) | 0.088c |
| Antacids, n (%) | 10 (59) | 14 (70) | 0.512c |
| Proton pump inhibitor, n (%) | 8 (47) | 12 (60) | 0.517c |
| Histamine H2-receptor antagonist, n (%) | 2 (12) | 2 (10) | 1.000c |
| Antipyretic analgesics, n (%) | 11 (65) | 7 (35) | 0.053c |
| NSAIDa, n (%) | 8 (47) | 6 (30) | 0.328c |
| Antihypertensive, n (%) | 5 (29) | 10 (50) | 0.315c |
aNon-Steroidal Anti-Inflammatory Drug, bWelch’s t-test, cFisher’s exact test